Cargando…

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma

Human multiple myeloma (MM) is characterized by accumulation of malignant terminally differentiated plasma cells (PCs) in the bone marrow (BM), raising the question when during maturation neoplastic transformation begins. Immunoglobulin IGHV genes carry imprints of clonal tumor history, delineating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowan, Graeme, Weston-Bell, Nicola J., Bryant, Dean, Seckinger, Anja, Hose, Dirk, Zojer, Niklas, Sahota, Surinder S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537010/ https://www.ncbi.nlm.nih.gov/pubmed/25929340

Ejemplares similares

Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes
por: Weston-Bell, Nicola J., et al.
Publicado: (2014)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2015)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
por: Schneller, Anja, et al.
Publicado: (2021)

Quantification of plasma cell dynamics using mathematical modelling
por: Mohr, Marcel, et al.
Publicado: (2018)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

The genomic landscape and clonal evolutionary trajectory of classical hairy cell leukemia
por: Moreno Rueda, Luz Yurany, et al.
Publicado: (2023)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
por: Hussmann, Dianna, et al.
Publicado: (2021)

Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival
por: Maichl, Daniela Simone, et al.
Publicado: (2023)

Celebrating 20 Years of IGHV Mutation Analysis in CLL
por: Chiorazzi, Nicholas, et al.
Publicado: (2020)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion
por: Weston-Bell, Nicola J., et al.
Publicado: (2016)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2018)

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
por: Ludwig, Heinz, et al.
Publicado: (2016)

Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
por: Tete, Sarah M., et al.
Publicado: (2014)

Association of an IGHV3-66 gene variant with Kawasaki disease
por: Johnson, Todd A., et al.
Publicado: (2020)

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis
por: Ludwig, Heinz, et al.
Publicado: (2023)

Erratum: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2017)

Correction: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2019)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

A programmable method for massively parallel targeted sequencing
por: Hopmans, Erik S., et al.
Publicado: (2014)

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model
por: Schulze, Felix, et al.
Publicado: (2017)

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
por: Bolomsky, Arnold, et al.
Publicado: (2016)

A Massively Parallel Sequencing Approach Uncovers Ancient Origins and High Genetic Variability of Endangered Przewalski's Horses
por: Goto, Hiroki, et al.
Publicado: (2011)

Focus on your locus with a massively parallel reporter assay
por: McAfee, Jessica C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1665qror4orl7u1aofbv40psds